Abstract
Women with germline BRCA1 or BRCA2 (BRCA1/2) mutations are considered as an extreme risk population for developing breast cancer. Prophylactic mastectomy provides a valid option to reduce such risk, impacting however, the quality of life. Medical prevention by aromatase inhibitor that has also recently shown to have preventive effect may thus be considered as an alternative. LIBER is an ongoing double-blind, randomized phase III trial to evaluate the efficacy of 5-year letrozole versus placebo to decrease breast cancer incidence in post-menopausal BRCA1/2 mutation carriers (NCT00673335). We present data on the uptake of this trial. We compared characteristics of women in the LIBER trial (n = 113) to those of women enrolled in the prospective ongoing national GENEPSO cohort (n = 1,505). Uptake was evaluated through a survey sent to all active centres, with responses obtained from 17 to the 20 (85%) centres. According to the characteristics of the women enrolled in the GENEPSO cohort and the survey, approximately one-third of BRCA1/2 mutation carriers were eligible for the trial. Five hundred and thirty-four women eligible from chart review have been informed by mail about the prevention trial and were invited to an oral information by participating centres. Forty-four percentage of them came to the dedicated medical visit. Uptake of drug prevention trial was 32% among women informed orally and 15% of all the eligible women. The main reasons of refusal were: potential side effects, probability to receive the placebo and lack of support from their physicians. Additionally, we noticed that prior prophylactic oophorectomy and previous unilateral breast cancer were more frequent in women enrolled in the LIBER trial than in the French cohort (93% vs. 60% and 50% vs. 39%, respectively). Based on an overall 15% uptake among all eligible subjects, greater and wider information of the trial should be offered to women with BRCA1/2 mutation to improve recruitment. Women with previous unilateral breast cancer or prior prophylactic oophorectomy are more likely to enter a medical prevention trial.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Antoniou A et al (2003) Average risks of breast and ovarian cancer associated with BRCA1/2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72(5):1117–1130
Robson M, Offit K (2007) Clinical practice. Management of an inherited predisposition to breast cancer. N Engl J Med 357(2):154–162
King MC, Marks JH, Mandell JB (2003) Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302(5645):643–646
Rebbeck TR et al (2004) Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE study group. J Clin Oncol 22(6):1055–1062
Klijn JEA (2004) Results of the extended series on prophylactic mastectomy versus surveillance in BRCA1/2 mutation carriers in Rotterdam. Breast Cancer Res Treat 88(Suppl 1):10
Meijers-Heijboer H et al (2001) Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1/2 mutation. N Engl J Med 345(3):159–164
Metcalfe KA, Semple JL, Narod SA (2005) Time to reconsider subcutaneous mastectomy for breast-cancer prevention. Lancet Oncol 6(6):431–434
Gahm J, Wickman M, Brandberg Y (2010) Bilateral prophylactic mastectomy in women with inherited risk of breast cancer: prevalence of pain and discomfort, impact on sexuality, quality of life and feelings of regret 2 years after surgery. Breast 19(6):462–469
Brandberg Y et al (2008) Psychological reactions, quality of life, and body image after bilateral prophylactic mastectomy in women at high risk for breast cancer: a prospective 1-year follow-up study. J Clin Oncol 26(24):3943–3949
Metcalfe KA et al (2008) International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int J Cancer 122(9):2017–2022
Habermann EB et al (2010) Are mastectomy rates really increasing in the United States? J Clin Oncol 28(21):3437–3441
Tuttle TM et al (2010) The increasing use of prophylactic mastectomy in the prevention of breast cancer. Curr Oncol Rep 12(1):16–21
McLaughlin CC, Lillquist PP, Edge SB (2005) Surveillance of prophylactic mastectomy: trends in use from 1995 to 2005. Cancer 115(23):5404–5412
Wood WC (2009) Should the use of contralateral prophylactic mastectomy be increasing as it is? Breast 18(Suppl 3):S93–S95
King MC et al (2001) Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: national surgical adjuvant breast and bowel project (NSABP-P1) breast cancer prevention trial. JAMA 286(18):2251–2256
Metcalfe KA (2009) Oophorectomy for breast cancer prevention in women with BRCA1/2 mutations. Womens Health (Lond Engl) 5(1):63–68
Domchek SM, Rebbeck TR (2007) Prophylactic oophorectomy in women at increased cancer risk. Curr Opin Obstet Gynecol 19(1):27–30
Kauff ND, Barakat RR (2007) Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1/2. J Clin Oncol 25(20):2921–2927
Noruzinia M, Coupier I, Pujol P (2005) Is BRCA1/2-related breast carcinogenesis estrogen dependent? Cancer 104(8):1567–1574
Rebbeck TR, Kauff ND, Domchek SM (2009) Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers. J Natl Cancer Inst 101(2):80–87
Jones LP et al (2008) Activation of estrogen signaling pathways collaborates with loss of BRCA1 to promote development of ER alpha-negative and ER alpha-positive mammary preneoplasia and cancer. Oncogene 27(6):794–802
Fisher B et al (2005) Tamoxifen for the prevention of breast cancer: current status of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst 97(22):1652–1662
Powles TJ et al (2007) Twenty-year follow-up of the royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst 9(4):283–290
Cummings SR et al (1999) The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple outcomes of raloxifene evaluation. JAMA 281(23):2189–2197
Vogel VG et al (2010) Update of the national surgical adjuvant breast and bowel project study of tamoxifen and raloxifene (STAR) P-2 trial: preventing breast cancer. Cancer Prev Res (Phila) 3(6):696–706
Cuzick J et al (2007) Long-term results of tamoxifen prophylaxis for breast cancer: 96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 99(4):272–282
Jordan VC (2007) Chemoprevention of breast cancer with selective oestrogen-receptor modulators. Nat Rev Cancer 7(1):46–53
Veronesi U et al (2007) Tamoxifen for the prevention of breast cancer: late results of the Italian randomized tamoxifen prevention trial among women with hysterectomy. J Natl Cancer Inst 99(9):727–737
Ropka ME, Keim J, Philbrick JT (2010) Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis. J Clin Oncol 28:3090–3095
Waters WA, Cronin KA, Graubard BI, Han PK, Freedman AN (2010) Prevalence of tamoxifen use for breast cancer chemoprevention among US women. Cancer Epidemiol Biomarkers Prev 19:443–446
Dowsett M et al (2010) Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 28(3):509–518
Goss PE et al (2007) National cancer institute of Canada clinical trials group MAP.3 trial: evaluation of exemestane to prevent breast cancer in postmenopausal women. Clin Breast Cancer 7(11):895–900
Cuzick J (2008) IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole. Expert Rev Anticancer Ther 8(9):1377–1385
Goss PE, Ingle JN, Alés-Martínez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, McTiernan A, Robbins J, Johnson KC, Martin LW, Winquist E, Sarto GE, Garber JE, Fabian CJ, Pujol P, Maunsell E, Farmer P, Gelmon KA, Tu D, Richardson H, NCIC CTG MAP.3 Study Investigators (2011) Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 364(25):2381–2391
Lecarpentier J, Noguès C, Mouret-Fourme E, Stoppa-Lyonnet D, Lasset C, Caron O, Fricker JP, Gladieff L, Faivre L, Sobol H, Gesta P, Frenay M, Luporsi E, Coupier I (2011) Variation in breast cancer risk with mutation position, smoking, alcohol, and chest X-ray history, in the French national BRCA1/2 carrier cohort (GENEPSO). GENEPSO, Lidereau R, Andrieu N. Breast Cancer Res Treat. 2011 Jul 15 (epub ahead of print)
Cuzick J et al (2003) Overview of the main outcomes in breast-cancer prevention trials. Lancet 361(9354):296–300
Evans D et al (2001) Uptake of screening and prevention in women at very high risk of breast cancer. Lancet 358(9285):889–890
Evans DG, Harvie M, Bundred N, Howell A (2010) Uptake of breast cancer prevention and screening trials. J Med Genet 47(12):853–855. Epub 2010 Oct 23
Graeser MK et al (2009) Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 27(35):5887–5892
Geisler J, Lonning PE (2010) Impact of aromatase inhibitors on bone health in breast cancer patients. J Steroid Biochem Mol Biol 118(4–5):294–299
Mortimer JE (2010) Managing the toxicities of the AI. Curr Opin Obstet Gynecol 22(1):56–60
Acknowledgments
Supported by Unicancer the French national cancer institute, the ligue nationale centre le cancer and Novartis.
Author information
Authors and Affiliations
Consortia
Corresponding author
Additional information
Trial Registration: Ongoing controlled trial NCT00673335.
Rights and permissions
About this article
Cite this article
Pujol, P., Lasset, C., Berthet, P. et al. Uptake of a randomized breast cancer prevention trial comparing letrozole to placebo in BRCA1/2 mutations carriers: the LIBER trial. Familial Cancer 11, 77–84 (2012). https://doi.org/10.1007/s10689-011-9484-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10689-011-9484-4